Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study

Ronan T Swords, Harry P. Erba, Daniel J. Deangelo, Dale L. Bixby, Jessica K. Altman, Michael Maris, Zhaowei Hua, Stephen J. Blakemore, Hélène Faessel, Farhad Sedarati, Bruce J. Dezube, Francis J. Giles, Bruno C. Medeiros

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days. Dose escalation proceeded using a standard '3 + 3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83 mg/m<sup>2</sup>, respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clinical activity was observed.

Original languageEnglish (US)
Pages (from-to)534-543
Number of pages10
JournalBritish Journal of Haematology
Volume169
Issue number4
DOIs
StatePublished - May 1 2015

Fingerprint

Myelodysplastic Syndromes
Enzyme Inhibitors
Acute Myeloid Leukemia
Appointments and Schedules
Maximum Tolerated Dose
((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo(2,3-d)pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulphamate
Intravenous Infusions
Pharmacokinetics
Guidelines
Enzymes

Keywords

  • Acute myeloid leukaemia
  • MLN4924
  • NEDD8
  • NEDD8-activating enzyme
  • Pevonedistat

ASJC Scopus subject areas

  • Hematology

Cite this

Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes : A phase 1 study. / Swords, Ronan T; Erba, Harry P.; Deangelo, Daniel J.; Bixby, Dale L.; Altman, Jessica K.; Maris, Michael; Hua, Zhaowei; Blakemore, Stephen J.; Faessel, Hélène; Sedarati, Farhad; Dezube, Bruce J.; Giles, Francis J.; Medeiros, Bruno C.

In: British Journal of Haematology, Vol. 169, No. 4, 01.05.2015, p. 534-543.

Research output: Contribution to journalArticle

Swords, RT, Erba, HP, Deangelo, DJ, Bixby, DL, Altman, JK, Maris, M, Hua, Z, Blakemore, SJ, Faessel, H, Sedarati, F, Dezube, BJ, Giles, FJ & Medeiros, BC 2015, 'Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study', British Journal of Haematology, vol. 169, no. 4, pp. 534-543. https://doi.org/10.1111/bjh.13323
Swords, Ronan T ; Erba, Harry P. ; Deangelo, Daniel J. ; Bixby, Dale L. ; Altman, Jessica K. ; Maris, Michael ; Hua, Zhaowei ; Blakemore, Stephen J. ; Faessel, Hélène ; Sedarati, Farhad ; Dezube, Bruce J. ; Giles, Francis J. ; Medeiros, Bruno C. / Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes : A phase 1 study. In: British Journal of Haematology. 2015 ; Vol. 169, No. 4. pp. 534-543.
@article{6b044b8bfe0141b48408ab80212b1449,
title = "Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 study",
abstract = "This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days. Dose escalation proceeded using a standard '3 + 3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83 mg/m2, respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17{\%} (4/23, 2 CRs, 2 PRs) for schedule A and 10{\%} (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clinical activity was observed.",
keywords = "Acute myeloid leukaemia, MLN4924, NEDD8, NEDD8-activating enzyme, Pevonedistat",
author = "Swords, {Ronan T} and Erba, {Harry P.} and Deangelo, {Daniel J.} and Bixby, {Dale L.} and Altman, {Jessica K.} and Michael Maris and Zhaowei Hua and Blakemore, {Stephen J.} and H{\'e}l{\`e}ne Faessel and Farhad Sedarati and Dezube, {Bruce J.} and Giles, {Francis J.} and Medeiros, {Bruno C.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/bjh.13323",
language = "English (US)",
volume = "169",
pages = "534--543",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes

T2 - A phase 1 study

AU - Swords, Ronan T

AU - Erba, Harry P.

AU - Deangelo, Daniel J.

AU - Bixby, Dale L.

AU - Altman, Jessica K.

AU - Maris, Michael

AU - Hua, Zhaowei

AU - Blakemore, Stephen J.

AU - Faessel, Hélène

AU - Sedarati, Farhad

AU - Dezube, Bruce J.

AU - Giles, Francis J.

AU - Medeiros, Bruno C.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days. Dose escalation proceeded using a standard '3 + 3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83 mg/m2, respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clinical activity was observed.

AB - This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n = 27), or days 1, 4, 8 and 11 (schedule B, n = 26) every 21-days. Dose escalation proceeded using a standard '3 + 3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83 mg/m2, respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clinical activity was observed.

KW - Acute myeloid leukaemia

KW - MLN4924

KW - NEDD8

KW - NEDD8-activating enzyme

KW - Pevonedistat

UR - http://www.scopus.com/inward/record.url?scp=84928426387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928426387&partnerID=8YFLogxK

U2 - 10.1111/bjh.13323

DO - 10.1111/bjh.13323

M3 - Article

C2 - 25733005

AN - SCOPUS:84928426387

VL - 169

SP - 534

EP - 543

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -